CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 55 enrolled
Drug / intervention
Erenumab-Aooe 140 MG/ML [Aimovig]drug
Likely dose
Erenumab-Aooe 140 MG/ML [Aimovig]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04465357
NCT04465357Phase 4Completed
CompareCT.gov

A Multicenter, Open Label Study Assessing the Efficacy of Erenumab on Functional Impact of Migraine

Merle Diamond·interventional·Posted Jul 10, 2020·Updated Oct 5, 2022

In Brief

A Phase 4 clinical trial evaluating Erenumab-Aooe 140 MG/ML [Aimovig] for Migraine. Completed, enrolled 55 participants across 3 sites.

Detailed Summary

The purpose of this study is to assess the efficacy of erenumab on functional impact due to Migraine in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsClinvest Research, LLC, Smith, Timothy R., M.D.

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 10, 2020
Enrollment StartOct 22, 2020
Primary CompletionJun 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.0 years ago

Interventions

Erenumab-Aooe 140 MG/ML [Aimovig]drug

140 mg/mL administered subcutaneously